AU2017298656A1 - Use of the IL-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis - Google Patents

Use of the IL-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis Download PDF

Info

Publication number
AU2017298656A1
AU2017298656A1 AU2017298656A AU2017298656A AU2017298656A1 AU 2017298656 A1 AU2017298656 A1 AU 2017298656A1 AU 2017298656 A AU2017298656 A AU 2017298656A AU 2017298656 A AU2017298656 A AU 2017298656A AU 2017298656 A1 AU2017298656 A1 AU 2017298656A1
Authority
AU
Australia
Prior art keywords
weeks
canakinumab
subject
use according
before treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017298656A
Other languages
English (en)
Other versions
AU2017298656A2 (en
Inventor
Stephen Oliver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2017298656A1 publication Critical patent/AU2017298656A1/en
Publication of AU2017298656A2 publication Critical patent/AU2017298656A2/en
Priority to AU2020207771A priority Critical patent/AU2020207771A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU2017298656A 2016-07-21 2017-07-19 Use of the IL-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis Abandoned AU2017298656A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020207771A AU2020207771A1 (en) 2016-07-21 2020-07-20 Use of the IL-1Beta binding antibody canakinumab for treating or alleviating symptoms of pulmonary sarcoidosis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662365017P 2016-07-21 2016-07-21
US62/365,017 2016-07-21
PCT/IB2017/054360 WO2018015897A1 (en) 2016-07-21 2017-07-19 Use of the il-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020207771A Division AU2020207771A1 (en) 2016-07-21 2020-07-20 Use of the IL-1Beta binding antibody canakinumab for treating or alleviating symptoms of pulmonary sarcoidosis

Publications (2)

Publication Number Publication Date
AU2017298656A1 true AU2017298656A1 (en) 2019-02-07
AU2017298656A2 AU2017298656A2 (en) 2019-03-28

Family

ID=59683618

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017298656A Abandoned AU2017298656A1 (en) 2016-07-21 2017-07-19 Use of the IL-1beta binding antibody canakinumab for treating or allevating symptoms of pulmonary sarcoidosis
AU2020207771A Abandoned AU2020207771A1 (en) 2016-07-21 2020-07-20 Use of the IL-1Beta binding antibody canakinumab for treating or alleviating symptoms of pulmonary sarcoidosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020207771A Abandoned AU2020207771A1 (en) 2016-07-21 2020-07-20 Use of the IL-1Beta binding antibody canakinumab for treating or alleviating symptoms of pulmonary sarcoidosis

Country Status (7)

Country Link
US (2) US20210292404A1 (cg-RX-API-DMAC10.html)
EP (1) EP3487584A1 (cg-RX-API-DMAC10.html)
JP (1) JP2019521161A (cg-RX-API-DMAC10.html)
KR (1) KR20190032436A (cg-RX-API-DMAC10.html)
AU (2) AU2017298656A1 (cg-RX-API-DMAC10.html)
CA (1) CA3031346A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018015897A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202400340D0 (en) 2024-01-10 2024-02-21 Wotherspoon Hugh Robert IL-1B binding antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
US10000565B2 (en) * 2012-11-16 2018-06-19 Novartis Ag Use of IL-1 β binding antibodies for treating peripheral arterial disease

Also Published As

Publication number Publication date
US20220177570A1 (en) 2022-06-09
EP3487584A1 (en) 2019-05-29
WO2018015897A1 (en) 2018-01-25
AU2017298656A2 (en) 2019-03-28
US20210292404A1 (en) 2021-09-23
KR20190032436A (ko) 2019-03-27
CA3031346A1 (en) 2018-01-25
AU2020207771A1 (en) 2020-08-06
JP2019521161A (ja) 2019-07-25

Similar Documents

Publication Publication Date Title
Khanna et al. Systemic sclerosis–associated interstitial lung disease: how to incorporate two food and drug administration–approved therapies in clinical practice
Lukey et al. A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Bisi et al. Rest technetium-99m sestmibi temography in combination with short-term administration of nitrates: Feasibility and reliability for prediction of postrevascularization outcome of asynergic territories
Lim et al. Assessment of coronary flow reserve with transthoracic Doppler echocardiography: comparison among adenosine, standard-dose dipyridamole, and high-dose dipyridamole
Chen et al. Quantifying pulmonary inflammation in cystic fibrosis with positron emission tomography
Dayton et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: implications for further studies
D'Alto et al. Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension
Alter et al. Left ventricular volume and wall stress are linked to lung function impairment in COPD
Hoeper et al. Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011
RU2706729C2 (ru) Способы лечения хронической обструктивной болезни легких с использованием бенрализумаба
Dreher et al. Exercise in severe COPD: is walking different from stair-climbing?
Ohar et al. Diffusing capacity decreases after heart transplantation
EP2844291B1 (en) Methods for treating idiopathic pulmonary fibrosis
Mura et al. Functional predictors of exertional dyspnea, 6-min walking distance and HRCT fibrosis score in idiopathic pulmonary fibrosis
Chen et al. [18F] fluorodeoxyglucose positron emission tomography for lung antiinflammatory response evaluation
Taylor et al. Effect of β2-adrenergic receptor stimulation on lung fluid in stable heart failure patients
Washko et al. Effect of dupilumab on small airways measured by airway oscillometry in VESTIGE
US20220177570A1 (en) Use of the il-1beta binding antibody canakinumab for treating or alleviating symptoms of pulmonary sarcoidosis
Zhao et al. Vericiguat combined with “new quadruple” therapy enhances cardiac function and life quality in patients with heart failure: a single-center prospective study
Villa et al. Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons
von Haehling et al. Iron deficiency in heart failure with preserved ejection fraction: rationale and design of the FAIR-HFpEF trial
Councils 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Ward et al. Interstitial lung disease: An approach to diagnosis and management
Bała et al. Management and treatment goals in Polish patients with type 2 diabetes of more than ten years’ duration—results of ARETAEUS2-Grupa Study
Matsushita et al. Use of [123I]-BMIPP myocardial scintigraphy for the clinical evaluation of a fatty-acid metabolism disorder of the right ventricle in chronic respiratory and pulmonary vascular disease

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 MAR 2019

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted